The Next Chapter of B7-H3: From Systemic Disease to the Brain

Data ReadoutpositiveB7-H3 Allogeneic CAR-TPositive

AI Analysis

Summary

T-MAXIMUM presented early data for its B7-H3 allogeneic CAR-T therapy in brain metastases at WCLC 2026. The presentation highlights expansion of B7-H3 ADC therapies from systemic disease to central nervous system applications.

Clinical Trial Data

Outcome Details

Early data for B7-H3 Allogeneic CAR-T in brain metastases presented at WCLC 2026

Importance:6/10

Sentiment:

0.60

CAR-TB7-H3brain metastasessmall cell lung cancerWCLC 2026allogeneic

Related Companies

$BNN.DE

Read the original article

Published by PR Newswire Biotech on September 21, 2026 11:50 AM

Read Original